Tempest Successful End-of-Phase 2 Meeting on Hepatocellular Carcinoma

 

• Broad agreement on pivotal Phase 3 study plan, including use of current amezalpat dose and schedule
  
• Overall survival, the strongest result from the Phase 2 trial, will be the primary study endpoint
• Agreed-upon early efficacy analysis could reduce time to primary read-out significantly

https://www.globenewswire.com/news-release/2024/08/15/2930848/0/en/Tempest-Announces-Successful-End-of-Phase-2-Meeting-with-FDA-for-Amezalpat-TPST-1120-to-Treat-First-Line-Hepatocellular-Carcinoma.html